Clovis Oncology, Inc. (NASDAQ:CLVS) Position Maintained by Shell Asset Management Co.
Shell Asset Management Co. continued to hold its stake in Clovis Oncology, Inc. (NASDAQ:CLVS) during the second quarter, Holdings Channel reports. The firm owned 7,680 shares of the biopharmaceutical company’s stock at the end of the second quarter. Shell Asset Management Co.’s holdings in Clovis Oncology were worth $719,000 as of its most recent filing with the SEC.
Other large investors have also recently bought and sold shares of the company. First Mercantile Trust Co. purchased a new stake in Clovis Oncology during the first quarter valued at about $115,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Clovis Oncology by 71.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,819 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 758 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Clovis Oncology by 3.7% in the first quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock valued at $179,000 after buying an additional 100 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Clovis Oncology during the first quarter valued at about $185,000. Finally, Ameritas Investment Partners Inc. purchased a new stake in Clovis Oncology during the first quarter valued at about $195,000. 90.67% of the stock is currently owned by institutional investors and hedge funds.
Shares of Clovis Oncology, Inc. (NASDAQ:CLVS) opened at 70.99 on Friday. The firm has a 50-day moving average of $87.18 and a 200-day moving average of $67.07. Clovis Oncology, Inc. has a 12-month low of $16.58 and a 12-month high of $99.45. The firm’s market cap is $3.47 billion.
Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by $0.02. The company had revenue of $14.62 million for the quarter, compared to analysts’ expectations of $13.07 million. During the same quarter in the prior year, the company posted ($2.07) earnings per share. The company’s quarterly revenue was down 32.5% compared to the same quarter last year. On average, equities analysts forecast that Clovis Oncology, Inc. will post ($7.51) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Clovis Oncology, Inc. (NASDAQ:CLVS) Position Maintained by Shell Asset Management Co.” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/12/clovis-oncology-inc-nasdaqclvs-position-maintained-by-shell-asset-management-co.html.
Several equities research analysts have recently issued reports on the stock. Bank of America Corporation lowered their target price on shares of Clovis Oncology from $103.00 to $75.00 and set a “buy” rating on the stock in a research note on Tuesday, June 20th. J P Morgan Chase & Co reissued an “overweight” rating and set a $111.00 target price (up from $72.00) on shares of Clovis Oncology in a research note on Tuesday, June 20th. Zacks Investment Research lowered shares of Clovis Oncology from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. Janney Montgomery Scott raised shares of Clovis Oncology from a “neutral” rating to a “buy” rating in a research note on Tuesday, June 20th. Finally, Morgan Stanley restated an “overweight” rating and set a $79.00 price target on shares of Clovis Oncology in a research report on Tuesday, June 20th. Eight research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $82.47.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $61.82, for a total value of $185,460.00. Following the sale, the insider now owns 200,583 shares of the company’s stock, valued at $12,400,041.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James C. Blair sold 18,450 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $78.61, for a total transaction of $1,450,354.50. Following the completion of the sale, the director now directly owns 2,185 shares in the company, valued at approximately $171,762.85. The disclosure for this sale can be found here. Insiders sold 27,450 shares of company stock worth $2,052,665 in the last ninety days. Insiders own 17.40% of the company’s stock.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology, Inc. (NASDAQ:CLVS).
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.